Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-08
2006-08-08
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S012200
Reexamination Certificate
active
07087577
ABSTRACT:
An angiogenic factor comprising a mixture of proteins derived from bone. The angiogenic protein mixture is produced by a series of steps that allow the proteins to be kept in solution. The angiogenic mixture of bone proteins is produced by a multi-step process that includes at least one ultrafiltration step, an anion exchange chromatography step, a cation exchange chromatography step and a high performance liquid chromatography (HPLC) purification step.
REFERENCES:
patent: 4529590 (1985-07-01), LeVeen et al.
patent: 4699788 (1987-10-01), Catsimpoolis et al.
patent: 4863732 (1989-09-01), Nathan et al.
patent: 4895838 (1990-01-01), McCluer et al.
patent: 4900673 (1990-02-01), Harper et al.
patent: 4950483 (1990-08-01), Ksander et al.
patent: 5116738 (1992-05-01), Wang et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5187076 (1993-02-01), Wozney et al.
patent: 5219576 (1993-06-01), Chu et al.
patent: 5270300 (1993-12-01), Hunziker
patent: 5290763 (1994-03-01), Poser et al.
patent: 5318957 (1994-06-01), Cid et al.
patent: 5328695 (1994-07-01), Lucas et al.
patent: 5371191 (1994-12-01), Poser et al.
patent: 5459047 (1995-10-01), Wozney et al.
patent: 5470831 (1995-11-01), Whitman et al.
patent: 5543392 (1996-08-01), Tomita et al.
patent: 5543394 (1996-08-01), Wozney et al.
patent: 5563124 (1996-10-01), Damien et al.
patent: 5595722 (1997-01-01), Grainger et al.
patent: 5616490 (1997-04-01), Sullivan et al.
patent: 5631142 (1997-05-01), Wang et al.
patent: 5635372 (1997-06-01), Celeste et al.
patent: 5637480 (1997-06-01), Celeste et al.
patent: 5656587 (1997-08-01), Sporn et al.
patent: 5661007 (1997-08-01), Wozney et al.
patent: 5677276 (1997-10-01), Dickerson et al.
patent: 5703043 (1997-12-01), Celeste et al.
patent: 5705477 (1998-01-01), Sporn et al.
patent: 5728679 (1998-03-01), Celeste et al.
patent: 5846770 (1998-12-01), LaVallie et al.
patent: 5849880 (1998-12-01), Wozney et al.
patent: 5854207 (1998-12-01), Lee et al.
patent: 5866364 (1999-02-01), Israel et al.
patent: 5902785 (1999-05-01), Hattersley et al.
patent: 5928940 (1999-07-01), Sampath et al.
patent: 5932216 (1999-08-01), Celeste et al.
patent: 5965403 (1999-10-01), Celeste et al.
patent: 5972884 (1999-10-01), Cohen et al.
patent: 5981489 (1999-11-01), Stevenson et al.
patent: 5994094 (1999-11-01), Hotten et al.
patent: 6051648 (2000-04-01), Rhee et al.
patent: 6120760 (2000-09-01), Hötten et al.
patent: 6124273 (2000-09-01), Drohan et al.
patent: 6150328 (2000-11-01), Wang et al.
patent: 6177406 (2001-01-01), Wang et al.
patent: 6197550 (2001-03-01), Hötten et al.
patent: 6211157 (2001-04-01), Benedict et al.
patent: 6372257 (2002-04-01), Marchosky
patent: 6468960 (2002-10-01), Lukanidin et al.
patent: 6498142 (2002-12-01), Sampath et al.
patent: 2002/0025340 (2002-02-01), Dyer
patent: 2003/0022828 (2003-01-01), Akella et al.
patent: 2003/0104977 (2003-06-01), Ripamonti et al.
patent: 1163780 (1997-11-01), None
patent: 0433225 (1991-06-01), None
patent: 0516901 (1992-12-01), None
patent: 0747066 (1996-12-01), None
patent: WO 97/41880 (1997-11-01), None
patent: WO 99/02674 (1999-01-01), None
patent: WO 99/31136 (1999-06-01), None
patent: WO 99/57146 (1999-11-01), None
patent: WO 02/00244 (2002-01-01), None
patent: WO 02/47713 (2002-06-01), None
patent: WO 03/060076 (2003-07-01), None
Ramoshebi et al. Osteogenic Protein-1, a Bone Morphogenetic Protein . . . The Anatomical Record. May 1, 2000, vol. 259, pp. 97-107.
B. Schumacher, et al, “Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors”, Clincial Investigation and Reports, American Heart Association 645-650 (1998).
Jamie P. Levine, et al, “Bone Morphogenetic Protein Promotes Vascularization and Osteoinduction in Preformed Hydroxyapatite in the Rabbit”, Annals of Plastic Surgery, vol. 39, 158-168 (1997).
Hidetoshi Yamashita, et al “Growth/Differentiation Factor-5 Induces Angiogenesis in Vivo”, Experimental Cell Research 235, 218-226 (1997).
Takashi Nakaoka et al, “Inhibition of Rat Vascular Smooth Muscle Proliferation in Vitro and In Vivo by Bone Morphogenetic Protein-2”, Journal of Clinical Investigation 100, 2824-2832 (1997).
Judah Folkman, “Angiogenic Therapy of the Human Heart”, American Heart Association, Inc., 628-629, (1998).
Cuevas et al., “Fibroblast Growth Factor Protects the Kidney Against Ischemia-Reperfusion Injury,”Eur. J. Med. Res., 4:403-10, 1999.
Freed et al., “Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers,”J. Biomed. Mater. Res., 27:11-23, 1993.
Freedman and Isner, “Therapeutic Angiogenesis for Ischemic Cardiovascular Disease,”J. Molecular and Cellular Cardiology, 33:379-93, 2001.
Hammerman, “Growth Factors in Renal Development,”Seminars in Nephrology, 15:291-99, 1995.
Hirschberg et al., “Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure,”Kidney International, 55:2423-32, 1999.
Kawa-uchi et al., “Fibroblast growth factor enhances expression of TGFβ-stimulated-clone-22 gene in osteoblast-like cells,”Endocrine, 3:833-37, 1995.
Laham et al., “Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia,”J. Pharmacol. Exp. Ther., 292:795-802, 2000.
Mueller et al., “Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment),”Swiss Med. Wkly, 131:23-25, 2001.
Nishida et al., “Adenovirus-Mediated Gene Transfer to Nucleus Pulposus Cells,”Spine, 23:2437-42, 1998.
Parsons-Wingerter et al., “A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection,”Microvasc. Res., 55:201-14, 1998.
Prochazka et al., “Epidermal Growth Factor and Insulin Growth Factor 1 Increase FSH-Stimulated Expansion of Porcine Cumulus Cells in Serum-free Medium,”J. Reproduction and Fertility, 25:64, 2000.
Sakaguchi et al., “A Combination of EGF and IGF-1 Accelerates the Progression of Meiosis in Bovine Follicular Oocytes In Vitro and Fetal Calf Serum Neutralizes the Acceleration Effect,”Theriogenology, 54:1327-42, 2000.
Stelnicki et al., “Bone Morphogenetic Protein-2 Induces Scar Formation and Skin Maturation in the Second Trimester Fetus,”Plastic and Reconstructive Surgery, 101:12-19, 1998.
Vukicevic et al., “Osteogenic Protein-1 (Bone Morphogenetic Protein-7) Reduces Severity of Injury After Ischemic Acute Renal Failure in Rat,”J. Clin. Invest., 102:202-14, 1998.
Wiley and Cunningham, “Epidermal Growth Factor Stimulates Fluid Phase Endocytosis in Human Fibroblasts Through a Signal Generated at the Cell Surface,”J. Cellular Biochem., 19:383-94, 1982.
Yamamoto et al., “Histologic evidence that basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization,”Basic Res. Cardiol., 95:55-63, 2000.
Yonggang et al., “Percutaneous injection of bone morphogenetic protein and polyvinyl pyrrolidone composite,”J. Xi' an Medical University, 22:132-33, 2001.
Akella Rama
Benedict James J.
Ranieri John P.
Whitney Marsha L.
Russel Jeffrey Edwin
William, Morgan & Amerson, P.C.
Zimmer OrthoBiologies, Inc.
LandOfFree
Method of promoting natural bypass does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of promoting natural bypass, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of promoting natural bypass will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691366